血管生成相关的lncRNAs指数:CESC预后,免疫疗法的有效性和化学敏感性的预测指标
Xueyuan Huang1, Guangming Yi2, Jiayu Xu3
1Clinical Medical College, Southwest Medical University, Luzhou 646000, China.
Journal of Cancer
|May 6, 2024
概括
这项研究开发了一种新的预后特征,使用血管生成相关的lncRNAs (ARLs) 来预测宫状细胞癌和宫内腺癌 (CESC) 患者的结果,从而可能提高免疫疗法的疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 子宫状细胞癌和子宫内腺癌 (CESC) 在晚期/复发阶段的预后不佳.
- 瘤血管生成是癌症进展和侵袭的关键因素.
- 识别新的预后标志物对于改善CESC患者的治疗结果至关重要.
研究的目的:
- 开发和验证基于血管生成相关的长非编码RNA (ARLs) 的预后特征,用于CESC.
- 探索ARLs与瘤免疫微环境之间的关系.
- 在CESC中提供预测预后和指导免疫治疗的工具.
主要方法:
- 使用单变量,多变量回归和拉索分析对七种与OS相关的ARL进行查.
- 在TCGA-CESC队列中开发和内部验证预后签名.
- 对免疫细胞透,免疫功能,免疫检查点,瘤突变负载和药物敏感性的全面分析.
主要成果:
- 建立并验证了基于七个ARL的强有力的预后签名.
- 签名有效地预测了CESC患者的预后.
- 在ARL和瘤免疫微环境的各种方面之间发现了显著的关联.
结论:
- 基于ARL的签名是预测CESC患者预后的有效工具.
- 签名提供了一个潜在的策略,以提高免疫疗法在CESC的疗效.
- 为了提高预测准确性,开发了一种结合签名和临床特征的诺米克图.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K